Revenue
2018
2019
2020
2021
2022
2023
2024
2025
AYTU BIOPHARMA, INC (AYTU)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M | $3.2M | $2.6M | $261,782 | — | — | — | — | — | — | — | — |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589,072 | $167,595 | $959,857 | $6.1M | $3.2M | — | — | — | — | — | — | — | — |
| Operating expenses | $53.7M | $50.6M | $83.7M | $162.2M | $88.1M | $40.5M | $24.2M | $23.4M | $23.3M | $24.3M | $7.9M | — | — | — | — | — | — | — | — |
| Operating income | −$7.8M | −$1.6M | −$17.1M | −$109.9M | −$58.9M | −$21.1M | −$16.8M | −$19.7M | −$20.1M | −$21.7M | −$7.6M | −$52,414 | −$56,356 | −$133,619 | — | — | — | — | — |
| EBITDAderived | −$2.5M | $6.7M | −$8.3M | −$99.8M | −$49.7M | −$15.4M | −$14.1M | −$17.1M | −$15.8M | −$20.8M | −$7.5M | $5,937 | −$2,947 | — | — | — | — | — | — |
| Net income | −$13.6M | −$15.8M | −$17.1M | −$108.8M | −$58.3M | −$13.6M | −$27.1M | −$10.2M | −$22.5M | −$28.2M | −$7.7M | −$57,318 | −$59,675 | −$136,802 | −$60,270 | −$58,894 | −$57,173 | −$48,954 | −$70,441 |
| Basic EPSper diluted share | -$2.16 | -$2.86 | -$5.11 | -$74.01 | -$3.48 | -$3.01 | -$3.48 | -$15.31 | -$48.30 | -$323.70 | -$10.07 | -$0.01 | -$0.01 | -$0.03 | — | — | — | — | — |
| Diluted EPSper diluted share | — | — | -$5.11 | -$74.01 | -$3.48 | -$3.01 | -$3.48 | -$15.31 | -$48.30 | -$323.70 | -$10.07 | -$0.01 | -$0.01 | -$0.03 | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 9, 2025Form 4 | Disbrow JarrettChief Business Officer | BuyCommon Stock | 16.7K | $1.50 | $25.0K | 29.5K |
| Jun 9, 2025Form 4 | Disbrow Joshua R.Chief Executive Officer | BuyCommon Stock | 66.7K | $1.50 | $100.0K | 153.3K |
| Jun 6, 2025Form 4 | Mack Daniel +2TenPercentOwner | BuyPrefunded Warrants · derivative · indirect | 4.00M | $1.50 | $6.00M | 4.82M |
| Feb 28, 2025Form 4 | Disbrow Joshua R.Chief Executive Officer | BuyCommon Stock | 15.0K | $1.30 | $19.5K | 86.6K |
| Dec 30, 2020Form 5 | DOCKERY CARLDirector | SellCommon Shares · indirect | 209 | $6.01 | $1.3K | 0 |